A Phase III, Multi-center, Randomized, Double Blind, Placebo-controlled, Single Dose, Trial to Demonstrate the Safety and Efficacy of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines

Trial Profile

A Phase III, Multi-center, Randomized, Double Blind, Placebo-controlled, Single Dose, Trial to Demonstrate the Safety and Efficacy of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2017

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Evolus
  • Most Recent Events

    • 09 Oct 2017 Results presented in an Evolus media release.
    • 09 Oct 2017 Primary endpoint (Efficacy - Reduction of Glabellar lines as assessed by investigator and subject) has been met according to an Evolus media release.
    • 09 Oct 2017 According to an Evolus media release, results from this trial will be presented at the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) and American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) meetings.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top